NewsNovo

Oragenics faces repeat NYSE listing breach as Phase IIa trial gains ground

8/30/2026

The case for Oragenics (NYSE American: OGEN) as a clinical-stage story is real: three active Australian trial sites, nine participants dosed on ONP-002, and FDA responses already arriving on the U.S.

What complicates it is a second deficiency letter from NYSE American, flagging the same equity shortfall the company only cleared in October 2025.

NYSE American notified Oragenics on August 26, 2026 that it is out of compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide.

The two provisions require listed companies reporting sustained net losses to maintain stockholders' equity of at least $4 million and $6 million, respectively.